Cargando…
Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues
Current regimen to treat patients suffering from stress urinary incontinence often seems not to yield satisfactory improvement or may come with severe side effects. To overcome these hurdles, preclinical studies and clinical feasibility studies explored the potential of cell therapies successfully a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036380/ https://www.ncbi.nlm.nih.gov/pubmed/35466714 http://dx.doi.org/10.1177/09636897221080943 |
_version_ | 1784693511855013888 |
---|---|
author | Geng, Ruizhi Knoll, Jasmin Harland, Niklas Amend, Bastian Enderle, Markus D. Linzenbold, Walter Abruzzese, Tanja Kalbe, Claudia Kemter, Elisabeth Wolf, Eckhard Schenk, Martin Stenzl, Arnulf Aicher, Wilhelm K. |
author_facet | Geng, Ruizhi Knoll, Jasmin Harland, Niklas Amend, Bastian Enderle, Markus D. Linzenbold, Walter Abruzzese, Tanja Kalbe, Claudia Kemter, Elisabeth Wolf, Eckhard Schenk, Martin Stenzl, Arnulf Aicher, Wilhelm K. |
author_sort | Geng, Ruizhi |
collection | PubMed |
description | Current regimen to treat patients suffering from stress urinary incontinence often seems not to yield satisfactory improvement or may come with severe side effects. To overcome these hurdles, preclinical studies and clinical feasibility studies explored the potential of cell therapies successfully and raised high hopes for better outcome. However, other studies were rather disappointing. We therefore developed a novel cell injection technology to deliver viable cells in the urethral sphincter complex by waterjet instead of using injection needles. We hypothesized that the risk of tissue injury and loss of cells could be reduced by a needle-free injection technology. Muscle-derived cells were obtained from young male piglets and characterized. Upon expansion and fluorescent labeling, cells were injected into cadaveric tissue samples by either waterjet or injection needle. In other experiments, labeled cells were injected by waterjet in the urethra of living pigs and incubated for up to 7 days of follow-up. The analyses documented that the cells injected by waterjet in vitro were viable and proliferated well. Upon injection in live animals, cells appeared undamaged, showed defined cellular somata with distinct nuclei, and contained intact chromosomal DNA. Most importantly, by in vivo waterjet injections, a significantly wider cell distribution was observed when compared with needle injections (P < .05, n ≥ 12 samples). The success rates of waterjet cell application in living animals were significantly higher (≥95%, n = 24) when compared with needle injections, and the injection depth of cells in the urethra could be adapted to the need by adjusting waterjet pressures. We conclude that the novel waterjet technology injects viable muscle cells in tissues at distinct and predetermined depth depending on the injection pressure employed. After waterjet injection, loss of cells by full penetration or injury of the tissue targeted was reduced significantly in comparison with our previous studies employing needle injections. |
format | Online Article Text |
id | pubmed-9036380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-90363802022-04-26 Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues Geng, Ruizhi Knoll, Jasmin Harland, Niklas Amend, Bastian Enderle, Markus D. Linzenbold, Walter Abruzzese, Tanja Kalbe, Claudia Kemter, Elisabeth Wolf, Eckhard Schenk, Martin Stenzl, Arnulf Aicher, Wilhelm K. Cell Transplant Original Article Current regimen to treat patients suffering from stress urinary incontinence often seems not to yield satisfactory improvement or may come with severe side effects. To overcome these hurdles, preclinical studies and clinical feasibility studies explored the potential of cell therapies successfully and raised high hopes for better outcome. However, other studies were rather disappointing. We therefore developed a novel cell injection technology to deliver viable cells in the urethral sphincter complex by waterjet instead of using injection needles. We hypothesized that the risk of tissue injury and loss of cells could be reduced by a needle-free injection technology. Muscle-derived cells were obtained from young male piglets and characterized. Upon expansion and fluorescent labeling, cells were injected into cadaveric tissue samples by either waterjet or injection needle. In other experiments, labeled cells were injected by waterjet in the urethra of living pigs and incubated for up to 7 days of follow-up. The analyses documented that the cells injected by waterjet in vitro were viable and proliferated well. Upon injection in live animals, cells appeared undamaged, showed defined cellular somata with distinct nuclei, and contained intact chromosomal DNA. Most importantly, by in vivo waterjet injections, a significantly wider cell distribution was observed when compared with needle injections (P < .05, n ≥ 12 samples). The success rates of waterjet cell application in living animals were significantly higher (≥95%, n = 24) when compared with needle injections, and the injection depth of cells in the urethra could be adapted to the need by adjusting waterjet pressures. We conclude that the novel waterjet technology injects viable muscle cells in tissues at distinct and predetermined depth depending on the injection pressure employed. After waterjet injection, loss of cells by full penetration or injury of the tissue targeted was reduced significantly in comparison with our previous studies employing needle injections. SAGE Publications 2022-04-23 /pmc/articles/PMC9036380/ /pubmed/35466714 http://dx.doi.org/10.1177/09636897221080943 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Geng, Ruizhi Knoll, Jasmin Harland, Niklas Amend, Bastian Enderle, Markus D. Linzenbold, Walter Abruzzese, Tanja Kalbe, Claudia Kemter, Elisabeth Wolf, Eckhard Schenk, Martin Stenzl, Arnulf Aicher, Wilhelm K. Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues |
title | Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues |
title_full | Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues |
title_fullStr | Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues |
title_full_unstemmed | Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues |
title_short | Replacing Needle Injection by a Novel Waterjet Technology Grants Improved Muscle Cell Delivery in Target Tissues |
title_sort | replacing needle injection by a novel waterjet technology grants improved muscle cell delivery in target tissues |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036380/ https://www.ncbi.nlm.nih.gov/pubmed/35466714 http://dx.doi.org/10.1177/09636897221080943 |
work_keys_str_mv | AT gengruizhi replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT knolljasmin replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT harlandniklas replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT amendbastian replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT enderlemarkusd replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT linzenboldwalter replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT abruzzesetanja replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT kalbeclaudia replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT kemterelisabeth replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT wolfeckhard replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT schenkmartin replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT stenzlarnulf replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues AT aicherwilhelmk replacingneedleinjectionbyanovelwaterjettechnologygrantsimprovedmusclecelldeliveryintargettissues |